Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Total Current Liabilities: 2017-2025

Historic Total Current Liabilities for Puma Biotechnology (PBYI) over the last 9 years, with Sep 2025 value amounting to $82.7 million.

  • Puma Biotechnology's Total Current Liabilities fell 25.06% to $82.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.7 million, marking a year-over-year decrease of 25.06%. This contributed to the annual value of $96.1 million for FY2024, which is 3.29% down from last year.
  • As of Q3 2025, Puma Biotechnology's Total Current Liabilities stood at $82.7 million, which was up 4.59% from $79.1 million recorded in Q2 2025.
  • Puma Biotechnology's 5-year Total Current Liabilities high stood at $140.4 million for Q1 2021, and its period low was $48.2 million during Q1 2023.
  • Its 3-year average for Total Current Liabilities is $84.8 million, with a median of $86.7 million in 2025.
  • As far as peak fluctuations go, Puma Biotechnology's Total Current Liabilities plummeted by 58.79% in 2022, and later spiked by 103.77% in 2024.
  • Quarterly analysis of 5 years shows Puma Biotechnology's Total Current Liabilities stood at $109.6 million in 2021, then decreased by 29.29% to $77.5 million in 2022, then grew by 28.26% to $99.4 million in 2023, then dropped by 3.29% to $96.1 million in 2024, then fell by 25.06% to $82.7 million in 2025.
  • Its Total Current Liabilities stands at $82.7 million for Q3 2025, versus $79.1 million for Q2 2025 and $86.7 million for Q1 2025.